Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

References

• Ministry of Health and Family Welfare. Government of India. Coronavirus Dashboard. National Informatics Centre. 2023 [accessed 2023 Feb 1]. https://www.mohfw.gov.in/.
   Google Scholar
• Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, et al. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021;42:101218. doi:10.1016/j.eclinm.2021.101218.
   PubMedGoogle Scholar
• World Health Organization. WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. WHO; 2021 [accessed 2023 Feb 1]. https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out.
   Google Scholar
• Jo DH, Minn D, Lim J, Lee KD, Kang YM, Choe KW, Kim K-N. Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination. Vaccines (Basel). 2021;9(10):1145. doi:10.3390/vaccines9101145.
   PubMed Web of Science ®Google Scholar
• Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, Roy T, Wieers G, Laurent C, Dogné J-M, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021;10(1):1495–8. doi:10.1080/22221751.2021.1953403.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, McMahan K, Liu J, Chandrashekar A, Patel S, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med. 2021;385(10):951–3. doi:10.1056/NEJMc2108829.
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW, Tieu H-V, Mayer KH, Corey L, Neuzil KM, et al. Durability of protection and immunogenicity of AZD1222 (ChAdox1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022 Sep 15;132(18):e160565. doi:10.1172/JCI160565.
   PubMed Web of Science ®Google Scholar
• Zhu L, Xu X, Zhu B, Guo X, Xu K, Song C, Fu J, Yu H, Kong X, Peng J, et al. Kinetics of SARS-CoV-2 specific and neutralizing antibodies over seven months after symptom onset in COVID-19 patients. Microbiol Spectr. 2021;9(2):e0059021. doi:10.1128/Spectrum.00590-21.
   PubMed Web of Science ®Google Scholar
• Griffante G, Chandel S, Ferrante D, Caneparo V, Capello D, Bettio V, Borgogna C, Aleni C, Esposito S, Sarro A, et al. Persistence of neutralizing antibodies to SARS-CoV-2 in first wave infected individuals at ten months post-infection: the UnIRSA cohort study. Viruses. 2021;13(11):2270. doi:10.3390/v13112270.
   PubMed Web of Science ®Google Scholar
• To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, Fong CHY, Yuan S, Tsoi H-W, Ng ACK, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2021;73(9):e2946–e51. doi:10.1093/cid/ciaa1275.
   PubMed Web of Science ®Google Scholar
• Chan PKS, Lui G, Hachim A, RLW K, Boon SS, Li T, Kavian N, Luk F, Chen Z, Yau EM, et al. Serologic responses in healthy adult with SARS-CoV-2 reinfection, Hong Kong, August 2020. Emerg Infect Dis. 2020;26(12):3076–8. doi:10.3201/eid2612.203833.
   PubMed Web of Science ®Google Scholar
• Gopinath S, Ishak A, Dhawan N, Poudel S, Shrestha PS, Singh P, Xie E, Tahir P, Marzaban S, Michel J, et al. Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: a systematic review. Trop Med Infect Dis. 2022;7(5):81. doi:10.3390/tropicalmed7050081.
   PubMedGoogle Scholar
• Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Thelwall S, Groves N, Dabrera G, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–50. doi:10.1056/NEJMoa2115481.
   PubMed Web of Science ®Google Scholar
• Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 delta variant and implications for vaccination. J R Soc Interface. 2022;19(191):20210900. doi:10.1098/rsif.2021.0900.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, Patel MK. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022;40(26):3516–27. doi:10.1016/j.vaccine.2022.04.069.
   PubMed Web of Science ®Google Scholar
• Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) COVID-19 vaccine. N Engl J Med. 2021;385(25):2348–60. doi:10.1056/NEJMoa2105290.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881–91. doi: 10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, Raut S, Kulkarni P, Apte A, Bavdekar A, et al. A phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults. Sci Rep. 2023;13(1):16579. doi:10.1038/s41598-023-43578-w.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76. doi:10.1016/S0140-6736(21)02717-3.
   PubMed Web of Science ®Google Scholar
• Rose W, Raju R, Babji S, George A, Madhavan R, Leander Xavier JV, David Chelladurai JS, Nikitha OS, Deborah AA, Vijayakumar S, et al. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study. Lancet Reg Health Southeast Asia. 2023;12:100141. doi:10.1016/j.lansea.2023.100141.
   PubMedGoogle Scholar